Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• Teva Pharmaceutical Industries Ltd. has received a consensus recommendation of "Buy" from nine brokerages, with an average 12-month price target of $25.57.
• Recent analyst upgrades include UBS and JPMorgan Chase raising their price targets to $26 and maintaining a favorable rating on the stock.
• Insider sales were noted, with significant transactions by Eric A. Hughes and Placid Jover, indicating potential changes in confidence from company executives.

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $25.5714.

TEVA has been the subject of a number of recent analyst reports. UBS Group upped their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, September 24th. JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an "overweight" rating in a report on Friday, October 3rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Saturday.

Insiders Place Their Bets

In related news, insider Eric A. Hughes sold 52,742 shares of the business's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the transaction, the insider owned 6,774 shares of the company's stock, valued at $102,693.84. The trade was a 47.19% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.55% of the company's stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently made changes to their positions in the stock. Bourgeon Capital Management LLC raised its stake in shares of Teva Pharmaceutical Industries by 100.7% during the 2nd quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company's stock valued at $12,134,000 after purchasing an additional 363,252 shares during the period. Amundi grew its holdings in Teva Pharmaceutical Industries by 18.5% during the 1st quarter. Amundi now owns 678,758 shares of the company's stock valued at $10,080,000 after buying an additional 105,846 shares in the last quarter. IFM Investors Pty Ltd boosted its position in shares of Teva Pharmaceutical Industries by 9.4% in the second quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company's stock valued at $3,797,000 after acquiring an additional 19,447 shares during the period. Jump Financial LLC boosted its position in shares of Teva Pharmaceutical Industries by 172.1% in the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company's stock valued at $20,373,000 after acquiring an additional 838,423 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Teva Pharmaceutical Industries by 5.7% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company's stock valued at $38,487,000 after acquiring an additional 134,705 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Up 0.5%

Teva Pharmaceutical Industries stock opened at $20.13 on Wednesday. Teva Pharmaceutical Industries has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The stock has a market cap of $23.08 billion, a PE ratio of -125.78, a price-to-earnings-growth ratio of 1.10 and a beta of 0.71. The firm's 50-day simple moving average is $18.69 and its 200 day simple moving average is $17.02. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm had revenue of $4.18 billion for the quarter, compared to analysts' expectations of $4.34 billion. During the same quarter last year, the firm earned $0.61 EPS. The company's quarterly revenue was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Research analysts predict that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.